Aldosterone Synthase Inhibitor Ameliorates Angiotensin II–Induced Organ Damage

Background—Aldosterone and angiotensin (Ang) II both may cause organ damage. Circulating aldosterone is produced in the adrenals; however, local cardiac synthesis has been reported. Aldosterone concentrations depend on the activity of aldosterone synthase (CYP11B2). We tested the hypothesis that reducing aldosterone by inhibiting CYP11B2 or by adrenalectomy (ADX) may ameliorate organ damage. Furthermore, we investigated how much local cardiac aldosterone originates from the adrenal gland. Methods and Results—We investigated the effect of the CYP11B2 inhibitor FAD286, losartan, and the consequences of ADX in transgenic rats overexpressing both the human renin and angiotensinogen genes (dTGR). dTGR-ADX received dexamethasone and 1% salt. Dexamethasone-treated dTGR-salt served as a control group in the ADX protocol. Untreated dTGR developed hypertension and cardiac and renal damage and had a 40% mortality rate (5/13) at 7 weeks. FAD286 reduced mortality to 10% (1/10) and ameliorated cardiac hypertrophy, albuminuria, cell infiltration, and matrix deposition in the heart and kidney. FAD286 had no effect on blood pressure at weeks 5 and 6 but slightly reduced blood pressure at week7 (177±6 mm Hg in dTGR+FAD286 and 200±5 mm Hg in dTGR). Losartan normalized blood pressure during the entire study. Circulating and cardiac aldosterone levels were reduced in FAD286 or losartan-treated dTGR. ADX combined with dexamethasone and salt treatment decreased circulating and cardiac aldosterone to barely detectable levels. At week 7, ADX-dTGR-dexamethasone-salt had a 22% mortality rate compared with 73% in dTGR-dexamethasone-salt. Both groups were similarly hypertensive (190±9 and 187±4 mm Hg). In contrast, cardiac hypertrophy index, albuminuria, cell infiltration, and matrix deposition were significantly reduced after ADX (P<0.05). Conclusions—Aldosterone plays a key role in the pathogenesis of Ang II–induced organ damage. Both FAD286 and ADX reduced circulating and cardiac aldosterone levels. The present results show that aldosterone produced in the adrenals is the main source of cardiac aldosterone.

[1]  C. Gomez-Sanchez,et al.  Origin of aldosterone in the rat heart. , 2004, Endocrinology.

[2]  J. Funder.  Cardiac synthesis of aldosterone: going, going, gone...? , 2004, Endocrinology.

[3]  G. Vinson,et al.  Mechanism for Aldosterone Potentiation of Angiotensin II–Stimulated Rat Arterial Smooth Muscle Cell Proliferation , 2004, Hypertension.

[4]  F. Luft,et al.  Aldosterone Potentiates Angiotensin II–Induced Signaling in Vascular Smooth Muscle Cells , 2004, Circulation.

[5]  Y. Takeda.  Vascular synthesis of aldosterone: role in hypertension , 2004, Molecular and Cellular Endocrinology.

[6]  M. Entman,et al.  Aldosterone, Through Novel Signaling Proteins, Is a Fundamental Molecular Bridge Between the Genetic Defect and the Cardiac Phenotype of Hypertrophic Cardiomyopathy , 2004, Circulation.

[7]  C. Stier,et al.  J Am Soc Nephrol 14: 1990–1997, 2003 Aldosterone Plays a Pivotal Role in the Pathogenesis of , 2022 .

[8]  S. MacKenzie,et al.  Extra‐adrenal production of corticosteroids , 2003, Clinical and experimental pharmacology & physiology.

[9]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[10]  R. Coleman,et al.  Effect of Eplerenone, a Selective Aldosterone Blocker, on Blood Pressure, Serum and Macrophage Oxidative Stress, and Atherosclerosis in Apolipoprotein E–Deficient Mice , 2003, Journal of cardiovascular pharmacology.

[11]  M. Horie,et al.  Immediate Administration of Mineralocorticoid Receptor Antagonist Spironolactone Prevents Post-Infarct Left Ventricular Remodeling Associated With Suppression of a Marker of Myocardial Collagen Synthesis in Patients With First Anterior Acute Myocardial Infarction , 2003, Circulation.

[12]  Takashi Yamamoto,et al.  Transcardiac Gradient of Aldosterone Before and After Spironolactone in Patients with Congestive Heart Failure , 2003, Journal of cardiovascular pharmacology.

[13]  Koichi Hayashi,et al.  Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy , 2003, Hypertension.

[14]  J. Delyani,et al.  Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. , 2002, Endocrinology.

[15]  S. Mildenberger,et al.  Human Epidermal Growth Factor Receptor-1 Expression Renders Chinese Hamster Ovary Cells Sensitive to Alternative Aldosterone Signaling* , 2002, The Journal of Biological Chemistry.

[16]  M. Zenke,et al.  Immunosuppressive treatment protects against angiotensin II-induced renal damage. , 2002, The American journal of pathology.

[17]  M. Kinoshita,et al.  Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. , 2001, Journal of the American College of Cardiology.

[18]  F. Luft,et al.  Mineralocorticoid Receptor Affects AP-1 and Nuclear Factor-&kgr;B Activation in Angiotensin II–Induced Cardiac Injury , 2001, Hypertension.

[19]  T. Saruta,et al.  Aldosterone Escape during Angiotensinconverting Enzyme Inhibitor Therapy in Essential Hypertensive Patients with Left Ventricular Hypertrophy , 2001, The Journal of international medical research.

[20]  K. Kugiyama,et al.  Aldosterone Production Is Activated in Failing Ventricle in Humans , 2001, Circulation.

[21]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[22]  I. Miyamori,et al.  Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. , 2000, Endocrinology.

[23]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[24]  A. Carayon,et al.  , Brigitte Angiotensin II Receptor Blockade and Role in Cardiac Fibrosis Activation of Cardiac Aldosterone Production in Rat Myocardial Infarction : Effect of , 1999 .

[25]  C. Stratakis,et al.  Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. , 1998, The Journal of clinical endocrinology and metabolism.

[26]  C. Delcayre,et al.  Myocardial Production of Aldosterone and Corticosterone in the Rat , 1998, The Journal of Biological Chemistry.

[27]  H. Morita,et al.  Aldosterone biosynthesis in the rat brain. , 1997, Endocrinology.

[28]  G. Condorelli,et al.  Dietary salt excess unmasks blunted aldosterone suppression and sodium retention in the stroke-prone phenotype of the spontaneously hypertensive rat , 1993, Journal of hypertension.

[29]  D. Ganten,et al.  Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. Kawamoto,et al.  Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. Vetter,et al.  Highly sensitive microassay for aldosterone in unextracted plasma: comparison with two other methods. , 1984, The Journal of laboratory and clinical medicine.

[32]  E. Schiffrin,et al.  Vascular Angiotensin II Receptors in Renal and DOCA‐Salt Hypertensive Rats , 1983, Hypertension.

[33]  K. Poulsen,et al.  An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. , 1974, The Journal of clinical endocrinology and metabolism.

[34]  D. Ganten,et al.  Hypertension-induced end-organ damage : A new transgenic approach to an old problem. , 1999, Hypertension.

[35]  I. Miyamori,et al.  Vascular aldosterone in genetically hypertensive rats. , 1997, Hypertension.

[36]  P. Vecsei.  39 – Glucocorticoids: Cortisol, Cortisone, Corticosterone, Compound S, and Their Metabolites , 1978 .

[37]  B. Jaffe,et al.  Methods of Hormone Radioimmunoassay , 1974 .